Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Issue 7 (August 2021)
- Record Type:
- Journal Article
- Title:
- Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Issue 7 (August 2021)
- Main Title:
- Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer
- Authors:
- Kobayashi, Satoshi
Ueno, Makoto
Ogawa, Gakuto
Fukutomi, Akira
Ikeda, Masafumi
Okusaka, Takuji
Sato, Tosiya
Ito, Yoshinori
Kadota, Tomohiro
Ioka, Tatsuya
Sugimori, Kazuya
Sata, Naohiro
Nakamori, Shoji
Shimizu, Kyoko
Mizuno, Nobumasa
Ishii, Hiroshi
Furuse, Junji - Abstract:
- Abstract : Supplemental digital content is available in the text. Abstract : Objectives: S-1 monotherapy with concurrent radiotherapy (RT) is a standard of care for patients with locally advanced pancreatic cancer (LAPC). Although renal dysfunction increases S-1 monotherapy toxicity, its effect in S-1 with concurrent RT remains unknown. We evaluated the effect of renal function on the safety of S-1 with RT for LAPC. Methods: We performed an integrated exploratory post hoc analysis of data from 2 prospective studies (JCOG1106 and LAPC-S1RT), where patients with LAPC received RT (50.4 Gy/28 fraction for 5.5 weeks) and concurrent S-1 (40 mg/m 2 per dose, twice daily on the day of irradiation). We split the patients into high creatinine clearance (CCr; ≥80 mL/min) and low CCr (<80 mL/min) groups and compared the findings to determine treatment safety. Results: The high and low CCr groups showed a median of 97.5 (range, 80.0–194.6) and 64.4 (range, 50.0–78.3) mL/min, respectively. The low CCr group presented more adverse reactions (ARs) of grade 3 or higher and gastrointestinal ARs of grade 2 or higher than the high CCr group (30.8% vs 15.8% and 51.9% vs 36.8%). Conclusions: The incidence of ARs associated with concurrent S-1 and RT increases in patients with low CCr; therefore, ARs should be duly considered in such patients.
- Is Part Of:
- Pancreas. Volume 50:Issue 7(2021)
- Journal:
- Pancreas
- Issue:
- Volume 50:Issue 7(2021)
- Issue Display:
- Volume 50, Issue 7 (2021)
- Year:
- 2021
- Volume:
- 50
- Issue:
- 7
- Issue Sort Value:
- 2021-0050-0007-0000
- Page Start:
- 965
- Page End:
- 971
- Publication Date:
- 2021-08
- Subjects:
- pancreatic cancer -- radiotherapy -- renal function -- S-1
Pancreas -- Diseases -- Periodicals
Pancreas -- Periodicals
Neuroendocrine tumors -- Periodicals
616.37005 - Journal URLs:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00006676-000000000-00000 ↗
http://www.pancreasjournal.com ↗
http://journals.lww.com/pancreasjournal/pages/default.aspx ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/MPA.0000000000001879 ↗
- Languages:
- English
- ISSNs:
- 0885-3177
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6357.351500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 19815.xml